4,093 Shares of DaVita Inc. $DVA Purchased by Axecap Investments LLC

Axecap Investments LLC purchased a new stake in DaVita Inc. (NYSE:DVA) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 4,093 shares of the company’s stock, valued at approximately $716,000.

A number of other hedge funds have also modified their holdings of DVA. Berkshire Hathaway Inc bought a new position in DaVita during the 2nd quarter worth approximately $6,425,269,000. BlackRock Inc. acquired a new stake in DaVita in the second quarter worth $547,520,000. Dimensional Fund Advisors LP boosted its position in shares of DaVita by 5.2% during the first quarter. Dimensional Fund Advisors LP now owns 1,145,436 shares of the company’s stock worth $176,037,000 after purchasing an additional 56,336 shares in the last quarter. Bank of America Corp DE bought a new position in shares of DaVita during the second quarter worth $145,057,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of DaVita in the 2nd quarter valued at $101,127,000. 90.12% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently commented on DVA. Oppenheimer set a $220.00 price objective on shares of DaVita in a research report on Friday, August 7th. TD Cowen raised DaVita from a “hold” rating to a “buy” rating and raised their price objective for the stock from $201.00 to $220.00 in a research note on Friday, August 7th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $265.00 target price on shares of DaVita in a report on Wednesday, August 5th. Weiss Ratings raised DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Friday, October 9th. Finally, Truist Financial lowered their price target on DaVita from $250.00 to $215.00 and set a “hold” rating for the company in a report on Friday, August 7th. Four analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $233.43.

DaVita Stock Down 6.3%

Shares of DVA stock opened at $175.13 on Wednesday. DaVita Inc. has a 12-month low of $101.00 and a 12-month high of $247.49. The firm has a fifty day moving average of $180.48 and a 200-day moving average of $191.24. The company has a market capitalization of $11.17 billion, a price-to-earnings ratio of 14.33, a P/E/G ratio of 0.48 and a beta of 0.80.

DaVita (NYSE:DVA) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $4.02 EPS for the quarter, beating the consensus estimate of $3.88 by $0.14. The business had revenue of $3.55 billion for the quarter, compared to analysts’ expectations of $3.50 billion. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The firm’s revenue was up 5.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.95 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, equities analysts expect that DaVita Inc. will post 14.57 EPS for the current year.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a health care services company focused on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis treatments for people with chronic kidney failure, including in-center hemodialysis, home dialysis and related clinical support services.

DaVita also offers integrated kidney care programs intended to support patients across the stages of chronic kidney disease. Its services may include care coordination, disease management, education, transplant support and other services designed to improve clinical outcomes and help manage the needs of patients with complex kidney conditions.

The company operates a network of dialysis centers and related facilities in the United States and serves patients in select international markets.